Chapter 29 Further Reading — The Peptide Drugs Already in Your Pharmacy

This chapter is unusual in that most of what it describes can be verified directly from primary regulatory documents rather than from review articles. Approved product labeling is public, free, and authoritative about exactly the thing this chapter cares about: what a drug is approved for, in whom, and with what warnings. Lean on it.

A note on how to read everything below: the goal is not to accumulate facts about individual molecules. It is to build a working sense of the shape of the approved pharmacopeia, so that §29.10's argument stops being something you were told and becomes something you have seen.

Tier 1 — Start here

Approved product labeling for four drugs from this chapter. Pull the current prescribing information for teriparatide, desmopressin, linaclotide, and icatibant from your national regulator's public database (in the US, the FDA's labeling repository; in the EU, the EMA's product information pages). Read only two sections of each: Indications and Usage and Warnings and Precautions.

This is the single highest-value hour in the chapter's reading list. Four labels will teach you more about how peptide drugs are actually positioned than any review article, because a label is the exact text a regulator was willing to defend. Pay attention to how narrow the indication statements are — the population, the setting, the qualifier. Nothing in this chapter's argument about box six will feel abstract after you have read four of these.

A current clinical practice guideline for osteoporosis from a major endocrine or rheumatology society. Read the section positioning anabolic versus antiresorptive agents. Guidelines are where the comparative evidence gets weighed openly, and where you can watch a field decide that a drug with a real effect nevertheless belongs in a narrow slot.

A general review of peptide therapeutics — search for a recent review of the approved peptide drug landscape in a journal such as Nature Reviews Drug Discovery, Drug Discovery Today, or Journal of Medicinal Chemistry. Choose one with a table of approved agents. Read the table before you read the prose, and count how many entries you had never heard of. Then look at how the review defines "peptide" — you will find the boundary problem from §29.1 stated explicitly, and different reviews drawing it in different places.

Any accessible account of the discovery of cyclosporine. Its isolation from a soil fungus and its effect on transplantation is one of the best-documented stories in twentieth-century pharmacology, and it is told well in several general histories of immunosuppression. Read it for the sequence of events, not the chemistry — the chemistry is in §29.8.

Tier 2 — Go deeper

The teriparatide fracture trial and the osteosarcoma labeling history. Find the pivotal randomized fracture-endpoint trial that supported approval, and then find the regulatory documentation of the boxed warning's removal. Reading the two together — nearly two decades apart — is the clearest available demonstration of a label following evidence in both directions.

The PROOF trial report and its critical commentary. Read the trial, then deliberately seek out methodological critiques of it. The dose-response and attrition issues discussed in §29.4 and Case Study 2 are laid out carefully in the secondary literature, and reading the primary report before the critique is a useful exercise in noticing what you do and do not spot on your own.

The European regulatory review of calcitonin (early 2010s) and the corresponding US advisory committee materials. Advisory committee briefing documents are underappreciated reading: they contain the manufacturer's case, the regulator's analysis, and the disagreement between them, in public. Very little other material shows you a live regulatory judgment being made.

VASST and VANISH. The two major randomized trials of vasopressin in septic shock. Read them alongside the current Surviving Sepsis Campaign recommendations to see how trial results with mixed implications get converted into a practice recommendation. This is a good corrective to the assumption that guidelines simply restate trials.

Comparative studies of glucagon administration by untrained users. Search for usability and human-factors studies comparing traditional reconstitution kits with nasal and ready-to-use liquid formulations. These are not glamorous papers and they are among the most quietly consequential in the chapter. They also demonstrate a research design most readers have never seen: the endpoint is whether a human being can operate the product correctly.

Reviews of macrocyclic and N-methylated peptides for oral bioavailability. The medicinal chemistry literature on "beyond rule of five" space is where cyclosporine's properties are systematically reverse-engineered. This is the direct bridge to Chapter 33.

Tier 3 — Specialist and historical

Bayliss and Starling's 1902 paper on secretin. Short, readable, and the origin of the hormone concept. Chapter 3's first case study covers it; reading the original is a pleasure and takes twenty minutes.

The primary literature on intermittent versus continuous PTH exposure in bone. The bone biology of why pulses build and continuity destroys remains an active area with competing accounts. Search for reviews of PTH signaling in osteoblast and osteoclast coupling. Expect to find genuine disagreement; that is the honest state of the mechanism, and §29.2 does not pretend otherwise.

The structural biology of vasopressin receptor subtypes. For readers who want to see how desmopressin achieves V2 preference at the level of receptor contacts rather than being told that it does.

Antimicrobial peptide reviews with a structural focus. The recurring cyclization theme across vancomycin, bacitracin, the polymyxins, and daptomycin is worth seeing laid out systematically. Chapter 25 covers the class; this is the chemistry underneath it.

WHO Model List of Essential Medicines. Not a reading in the usual sense — a document to scan. Go through it looking for peptides. The exercise takes fifteen minutes and does more for the chapter's central argument than any amount of prose, including this chapter's.

Regulatory guidance on the Unapproved Drugs Initiative. For readers curious how a drug in routine hospital use for decades comes to receive a "new" approval in the mid-2010s, as vasopressin did. It is a small window into how much of medicine predates the framework that now governs it.

If you only do one thing

Open your national regulator's public drug database and read the "Indications and Usage" section of five approved peptide drug labels — chosen from this chapter, not from the famous ones. Suggested set: teriparatide, desmopressin, cosyntropin, linaclotide, icatibant.

Then, for each, write down which of the six functional boxes from §29.10 the indication falls into.

It will take you under an hour. When you are done, you will have built the chapter's central argument yourself, out of primary sources, without taking anyone's word for it — and you will have noticed the thing that matters most, which is not what is in those five labels but what is not in any of them.